Laser therapy vs sclerotherapy (any sclerosant)
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Laser therapy vs sclerotherapy (any sclerosant)
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Laser therapy vs sclerotherapy (any sclerosant)
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sunlight (with or without filters or amplification) vs other sources of phototherapy
Treatment failure requiring exchange transfusionc,d · infants with confirmed hyperbilirubinemia
Sunlight (with or without filters or amplification) showed no clear difference in treatment failure requiring exchange transfusionc,d compared with other sources of phototherapy (low certainty).
1 finding from 1 review
- Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates 2021 · Cochrane Headline outcomes onlyRR 1 [0.06, 15.73]2 studies · 621 participantsLow
Sunlight (with or without filters or amplification) vs other sources of phototherapy
Acute bilirubin encephalopathy · infants with confirmed hyperbilirubinemia
Sunlight (with or without filters or amplification) may leads to lower acute bilirubin encephalopathyc,f compared with other sources of phototherapy (low certainty).
1 finding from 1 review
- Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates 2021 · Cochrane Headline outcomes onlyRR 01 study · 174 participantsLow
Sunlight (with or without filters or amplification) vs other sources of phototherapy
Deathc · infants with confirmed hyperbilirubinemia
Sunlight (with or without filters or amplification) may leads to lower deathc compared with other sources of phototherapy (low certainty).
1 finding from 1 review
- Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates 2021 · Cochrane Headline outcomes onlyRR 01 study · 447 participantsLow
Sunlight (with or without filters or amplification) vs other sources of phototherapy
Proportion of days of effective treatmenti · infants with confirmed hyperbilirubinemia
It is very uncertain whether sunlight (with or without filters or amplification) changes proportion of days of effective treatmenti compared with other sources of phototherapy (very low certainty).
1 finding from 1 review
- Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates 2021 · Cochrane Headline outcomes onlyRR 1.02 [0.97, 1.06]2 studies · 621 participantsVery low
Sunlight (with or without filters or amplification) vs other sources of phototherapy
Outcomesa · infants with confirmed hyperbilirubinemia
The review found no eligible studies for this question.
1 finding from 1 review
- Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Yoga vs no treatment (both groups received standard medical therapy)
Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Yoga vs no treatment (both groups received standard medical therapy)
Abdominal pain frequency or change in frequency · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Yoga vs no treatment (both groups received standard medical therapy)
Abdominal pain intensity or change in intensity · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Yoga vs no treatment (both groups received standard medical therapy)
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 100 participantsVery low
Azathioprine vs cyclophosphamide
Death (all causes) · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in death (median compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 0.77 [0.35, 1.72]1 study · 144 participantsModerate
Azathioprine vs cyclophosphamide
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Azathioprine vs cyclophosphamide
Dialysis · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in dialysis (median compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1.65 [0.57, 4.79]1 study · 144 participantsModerate
Azathioprine vs cyclophosphamide
Relapse · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).
2 findings from 1 review
- RR 1.13 [0.51, 2.5]1 study · 144 participantsModerate
- RR 1.46 [1, 2.14]1 study · 144 participantsModerate
Azathioprine vs cyclophosphamide
Serious adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1.18 [0.45, 3.07]1 study · 144 participantsModerate
Azathioprine vs cyclophosphamide
Infections · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in infections compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1.03 [0.51, 2.06]1 study · 144 participantsModerate
Azathioprine vs methotrexate
Death · adults with renal vasculitis for maintenance therapy
Azathioprine may leads to lower death compared with methotrexate (low certainty).
1 finding from 1 review
- RR 0.331 study · 126 participantsLow
Azathioprine vs methotrexate
Kidney function · adults with renal vasculitis for maintenance therapy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found